Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors

Conclusions The RP2D was not defined and the pimasertib plus temsirolimus combination investigated did not warrant further study.

Source: Investigational New Drugs - February 12, 2017 Category: Drugs & Pharmacology Source Type: research